Shanghai – Antengene Corporation a biopharmaceutical company, announced on 13th of July the appointment of Dirk Hoenemann, M.D as VP, Head of Medical Affairs for Asia Pacific Region (APAC) and Early Clinical Development. He will be reporting directly to Mr. Thomas Karalis, Head of Asia Pacific Region and Jay Mei, M.D., Ph.D., CEO of Antengene Corporation
“Following the SNDA of ATG-010 in DLBCL last month in the U.S., we are thrilled to have Dirk join the team today and bring his profound global translational research and clinical development experience to the team. Dirk is a highly accomplished oncology researcher and an outstanding leader with impressive ability to lead teams of highly qualified individuals in high pressure environments. I believe he will play an essential role in boosting Antengene’s growth in the Asia Pacific Region so as to achieve our mission of treating and making a positive difference in the lives of cancer patients in these markets.” said Jay Mei, M.D., Ph.D., Chairman and CEO of Antengene
In this role, Dirk will be responsible for establishing the Antengene APAC Medical Affairs function, structure and processes, and the clinical development strategies for multiple early phase compounds/programs. Dirk has over 20 years of experience in clinical research, translational medicine, academia, and the pharmaceutical industry. He has led multiple clinical programs, including first-in-human initiatives with novel antibody formats in hematological malignancies and solid tumors, and has made critical contributions to the first CAR-T study in Australia targeting LewisY. Dirk has also held numerous leadership positions in the pharmaceutical industry. In his most recent role at Celgene, he led the development of Early Clinical Development programs for the Asia Pacific Region and the successful launches of lenalidomide, pomalidomide, and azacitidine in some APAC markets.
Dr. Dirk Hoenemann said: “I feel honored to join Antengene, a pharmaceutical company dedicated to the research of advanced and novel medicines. Besides, it’s my privilege to have the opportunity to lead the company’s Medical Affairs & Early Clinical Development and bring forward the company’s strong pipeline of medicines that meet the unmet medical needs in the Asia Pacific Region and worldwide. “
Dirk earned his Doctor of Medicine from Charite, University Hospital Berlin, and Internal Medicine from University of Würzburg.